Safety of anagliptin/metformin combination tablets evaluated by non-inferiority between pre- and post-serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY).

J Diabetes Investig · 2026 · PMC13042598 · PMID 41641475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

The advantages of using the combination drugs of DPP‐4 inhibitors and metformin are extremely significant in patients with type 2 diabetes and renal dysfunction.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.